CONFERENCE DAY TWO
WEDNESDAY, MARCH 27

7.30 Registration & Morning Coffee

8.20 Chairperson Opening Remarks

Highlighting Organizations that Provide Support to Projects Targeting Drug-Resistant Bacteria

8.30

Highlighting How CARB-X’s Portfolio is Growing and Diversifying in the Race Against Superbugs

Download the event guide for full session details

Karen Gallant
Global Project Director
CARB-X

Moving Beyond ‘Therapy’ in the Strictest Sense – Using Phages as Probiotics & in Prophylactic Settings

Introduction and Purpose:
Whilst commercialization of phage therapeutics with curative outcomes is the primary goal of the phage development community, multiple hurdles have often slowed the progression of phage therapy to market. The purpose of this theme will be to explore how bacteriophages are being developed for use in other contexts as probiotics in combination with antibiotics or in prophylactic settings as first line therapies.

9.00

Innovating with Bacteriophage Products: Two Sides of the Coin

Download the event guide for full session details

Yug Varma
CEO
Phi Therapeutics

9.30

Utilizing Bacteriophages to Prevent Infections – Advanced Topical Delivery Systems

Download the event guide for full session details

Mark Engel
Chairman & CEO
Phagelux

Defining Tools that Facilitate Pre-Clinical Modelling and Accelerate Pre-Clinical Candidates Through the Product Development Pipeline

Introduction and Purpose:
It has been difficult to simulate phage pharmacology that replicates in vivo conditions and interactions in the preclinical setting. Given that conventional pharmacokinetic and pharmacodynamic models are not entirely applicable for phage therapy, this theme will focus on tools being used to help progress pre-clinical phage candidates into the clinic.

10.00

Balancing Regulatory Requirements with Practical Needs in Synthetic Phage Development

Download the event guide for full session details

Chris Kaplan
Director, Product Development
C3J Therapeutics

10.30 Morning Refreshments & Networking

11.00

Phagomed: Bringing Phage Therapy to Patients

Download the event guide for full session details

Lorenzo Corsini
Co-Founder, CEO, R&D
PhagoMed

Formulation & Production Methods Amenable to Scale Up & Delivery of Stable Products

Introduction and Purpose:
The industry remains united in its challenges in achieving Good Manufacturing Practice (GMP) compliance for phage product formulation and questions remain unanswered about the most suitable routes of administration in different disease settings. It is also unclear what defines efficient and cost-effective production of stable and high quality phage therapy on both an individual and industrial scale. This session will clarify how to streamline production processes and optimize phage amplification, purification, encapsulation and delivery kinetics that are clinically meaningful.

11.30

Scalable Production and Encapsulation Methods for Bacteriophage Therapy

Download the event guide for full session details

Danish Malik
Senior Lecturer
University of Loughborough

12.00

Panel Discussion: How can Manufacturing Processes and New Approaches Towards Formulation of Phage Therapy be Optimized to Become More Clinically Relevant?

Download the event guide for full session details

Clara Leandro
Senior Scientist
Technophage

Yug Varma
CEO
Phi Therapeutics

Danish Malik
Senior Lecturer
University of Loughborough

Brian Varnum
Chief Development Officer
C3J Therapeutics

12.30 Lunch & Networking

Harnessing Clinical Experience to Establish Gold Standards for Phage Therapy Clinical Trials

Introduction and Purpose:
Safety and effectiveness of phage therapy has been demonstrated in clinical practice across Eastern Europe but these products have only been used in expanded access trials across Western Europe and the States. The purpose of this theme will be to leverage learnings from case studies and understand the first-hand clinical experience of administering phage therapy in order to establish key considerations for good clinical trial design for these products.

13.30

The Pathway from Bench to Bedside: Lysin CF–301 (exebacase) - A Case Study

Download the event guide for full session details

Cara Cassino
Executive VP of R&D & CMO
ContraFect

Future Horizons: Commercializing & Delivering Phage Therapy into the Hands of Physicians & Patients in Need

Introduction and Purpose:
As phage therapy begins to penetrate the clinical arena, understanding how to leverage collaborative networks and the best ‘go to market’ strategies for these products will be critical in ensuring their commercial success. This theme will allow reflection upon the opportunity that lies in being at this stage of product development, in shaping, influencing and defining the future of phage therapy.

14.00

14.30

Translating Personalized Phage Therapy to Commercial Scale

Download the event guide for full session details

Bacteriophages Alliances in Ferring

Download the event guide for full session details

Greg Merril
Co-Founder & CEO
Adaptive Phage Therapeutics

Kristin Wannerberger
Director R&D Alliance Management
Ferring Pharmaceuticals

15.00 Chairperson Closing Remarks

15.10 End of Summit